Graft-Versus-Host Disease (GvHD): Non-Steroidal Treatments — Market Insight 2023 with Wissen Research

Graft Versus Host Disease (GVHD): Disease Overview

For Full Read — https://www.wissenresearch.com/graft-versus-host-disease-market-report-2023/

Graft versus host disease (GvHD) is a potentially life-threatening complication that can occur after a stem cell or bone marrow transplant from another person. During an allogeneic transplant, the donated stem cells from a donor recognize the recipient’s body as foreign and attack it.

This can lead to two types of GvHD: Acute and Chronic.

Acute GvHD:

Acute GvHD usually occurs within the first 100 days after the transplant and is characterized by an inflammatory reaction that affects the skin, gastrointestinal tract, and liver. Symptoms may include skin rash, diarrhea, abdominal pain, nausea, vomiting, and jaundice. Acute GvHD can be further classified into grades I-IV, depending on the severity of symptoms.

Chronic GvHD:

Chronic GVHD usually occurs after day 100 and can last for several months to years. It can affect multiple organs and may present with a variety of symptoms, such as skin rash, dry mouth, dry eyes, joint pain, fatigue, and weight loss. Chronic GvHD can also be classified into mild, moderate, or severe, based on the extent and severity of organ involvement.

Staging of GVHD:

To better manage and treat GvHD, it is important to stage the disease accurately. The most widely used staging system for acute GvHD is the Glucksberg criteria, which classifies the disease into four stages based on the severity of organ involvement and the degree of immunosuppression required for treatment. The National Institutes of Health (NIH) consensus criteria are commonly used to stage chronic GvHD and classify it into mild, moderate, or severe.

Treatment of GvHD:

The treatment of GvHD depends on the type, severity, and extent of organ involvement. Treatment for GvHD includes drugs that suppress or calm the immune system, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies.

Mild cases of acute GvHD may be managed with topical or systemic corticosteroids, while severe cases may require additional immunosuppressive therapies, such as cyclosporine, tacrolimus, or anti-thymocyte globulin (ATG). Chronic GvHD is usually managed with a combination of corticosteroids and immunosuppressive agents.

Steroids are the mainstay of treatment for GvHD. However, some patients may not respond adequately to steroids, which is referred to as steroid refractory GvHD. In this condition, GvHD that does not improve with high doses of steroids (e.g., prednisone) or that progresses despite treatment with steroids.

On the other hand, some patients may respond initially to steroids but become dependent on them to control GVHD, which is referred to as steroid dependent GVHD. This means that reducing or stopping steroid treatment can cause GVHD symptoms to return.

Overall, steroid refractory and steroid dependent GVHD are challenging conditions that require careful management. The approach to both steroid-dependent and steroid-refractory GVHD is the same, which is to go to a second-line treatment (steroid free approaches).

Research is ongoing to improve the prevention and treatment of Steroid Refractory and Steroid Dependent GvHD. Some promising approaches include using mesenchymal stem cells, regulatory T cells, Extracorporeal photopheresis or other cell therapies to modulate the immune response and reduce inflammation.

Geography

• Technology covered: Worldwide
• Market covered: USA, Europe and Japan

Time Period

• For technology coverage: 2020 till present
• For market analysis: 2023 till 2033

Graft Vs Host Disease non-steroidal treatments Report Key Strengths

• 10-Years Forecast
• Top players
• Treatments approach segmentation
• KOL analysis insights
• SWOT of treatments
• Opportunity (Licensees and suppliers)
• Highly Analysed Graft Vs Host Disease non-steroidal treatments Market

Graft Vs Host Disease non-steroidal treatments Report Assessment

• Current Graft Vs Host Disease non-steroidal treatments Practices
• Unmet Needs
• Approved Product Profiles
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• Therapeutic assessment of drugs

Graft Vs Host Disease non-steroidal treatments Market Report Highlights

• The Graft Versus Host disease market is expected to change over the next few years as a result of increased global healthcare spending and increased knowledge of the condition. This will increase the market’s size and allow pharmaceutical companies to extend their market share.
• Companies and academics working on Graft Versus Host Disease are evaluating obstacles and looking for opportunities that may have an impact on R&D. The focus of the currently being developed therapies is on cutting-edge methods to treat or ameliorate the disease state.
• The development of treatments for Graft Versus Host Disease is being done by companies. The market for therapy for Graft Versus Host Disease will be greatly impacted by the launch of new treatments.
• By identifying the general context of the research and development activities, our in-depth analysis of the pipeline assets at various stages of development (phase III and phase II), various emerging trends, comparative analysis of pipeline products with clinical profiles, kol’s , patent filing, launch date, and product development activities will assist the clients in making decisions regarding their drug delivery portfolio.

Reasons to buy

• By comprehending the trends influencing and driving Graft Vs Host Disease non-steroidal treatment strategies, the report will aid in the development of business strategies.
• To comprehend the future market of Graft Vs Host Disease non-steroidal treatment, also market competition and to gain a thorough understanding of the major market drivers and obstacles.
• Finding strong opportunities in the market that will aid in the development of tactics for edging out rivals.
• Comprehension of how the market for Graft Vs Host Disease will be competitive in the future.
• Detailed patent examination to look for novelty in drug delivery techniques for Graft Vs Host Disease non-steroidal treatments